Skip to main content

Should I Buy NASDAQ:MEIP Stock? (6% Forecasted Return) | MEIP MEI Pharma Stock Forecast



The various qualitative factors in the criteria help to identify strengths and weaknesses within a company's future liquidity position that numerical ratios might not fully capture. While there is no size bias in our liquidity assessment, generally, lower-rated entities might meet the quantitative requirements for strong or exceptional liquidity but fail to meet corresponding qualitative factors.In determining how prudent a company's risk management is, we look for evidence that management has historically anticipated potential company-specific or market-related setbacks and has taken necessary actions to ensure sufficient liquidity. We estimate MEIP MEI Pharma stock forecast parameters by: Rating with Logistic Regression because explicitly excluded by regulation from those liabilities that may be bailed in if the obligor enters a bail-in resolution (6% Forecasted Return)

NASDAQ:MEIP Stock Forecast (Buy or Sell) as of 22 Jun 2022 for (n+8 weeks)

Stock: MEIP MEI Pharma

Time series to forecast n: 22 Jun 2022 for (n+8 weeks)

x axis:Likelihood %
y axis:Potential Impact %
z axis:Color (yellow to green) Technical Analysis %

Stock Forecast Criteria and Models for MEIP MEI Pharma

  • The replacement issuance does not, in our view, materially weaken the creditworthiness of the issuer, including that it will not cause a lowering of the long-term credit rating or cause a downward revision to the outlook on the long-term credit rating.
  • In our general classification of asset classes and corresponding risk weights, we aim to accurately differentiate the risks generally on entities' balance sheets on a globally consistent basis. But occasionally, a financial system or institution may have unique risks that we choose to capture by reclassifying exposures to alternative asset classes than the ones we typically use. We do this to reflect our expectation of materially and consistently higher or lower losses for that unique set of exposures for a system or an entity than likely would be the case for the typically corresponding asset class in the given BICRA, economic risk, or rating category.
  • We only include the surplus on PRB in our calculation of ACE to the extent that the relevant regulator recognizes the surplus in its measure of capital. This is because we take this as an indication that the institution has access to the assets in the fund and we believe that it can use the surplus. Otherwise, we exclude the surplus from our calculation of ACE.
  • Financial institutions face risks that arise from their balance sheets and operations. They manage these through their risk management and governance, and they shield senior bondholders from these risks using their capital and earnings. We expect that in a typical economic cycle, on average, firms will have earnings sufficient to absorb normal (or expected) losses.
  • For some asset classes, the estimation may proceed in stages: We might separately estimate asset default frequencies and loss severities under extreme stress conditions and then combine those components to form the overall loss estimate.
  • Holding companies are typically reliant on dividends and other distributions from operating companies to meet their obligations. The rating of holding companies of prudentially regulated financial services groups reflects the difference in their creditworthiness relative to the group's operating entities. The rating differential is mainly due to the increased credit risk that arises from possible regulatory constraints to upstream resources and potentially different treatment under a default scenario.
  • We do not rate a hybrid instrument if it has a loss-absorption or cash conservation trigger that is not related to the issuer's creditworthiness.

Assumptions Underlying The Forecast Model for MEIP MEI Pharma

Our view of a company's financial policy is an important input when assessing its current and future liquidity position. For instance, we assess whether a company has historically had a higher risk appetite and an aggressive acquisition strategy that has strained its liquidity position, or whether it has taken actions to preserve liquidity in past downturns.

Frequently Asked QuestionsQ: Is MEIP MEI Pharma stock buy or sell?
A: The various qualitative factors in the criteria help to identify strengths and weaknesses within a company's future liquidity position that numerical ratios might not fully capture. While there is no size bias in our liquidity assessment, generally, lower-rated entities might meet the quantitative requirements for strong or exceptional liquidity but fail to meet corresponding qualitative factors.
Q: Is MEIP MEI Pharma stock expected to go up?
A: In determining how prudent a company's risk management is, we look for evidence that management has historically anticipated potential company-specific or market-related setbacks and has taken necessary actions to ensure sufficient liquidity.
Q: What is the forecast for MEIP MEI Pharma ?
A: Our view of a company's financial policy is an important input when assessing its current and future liquidity position. For instance, we assess whether a company has historically had a higher risk appetite and an aggressive acquisition strategy that has strained its liquidity position, or whether it has taken actions to preserve liquidity in past downturns.
Q: What is the consensus rating of MEIP MEI Pharma ?
A: The consensus rating for MEIP MEI Pharma is 90.
Q: What are the risks of investing MEIP MEI Pharma ?
A: We use risk analysis for MEIP MEI Pharma because explicitly excluded by regulation from those liabilities that may be bailed in if the obligor enters a bail-in resolution


MEIP MEI Pharma